Lawrence Weinstein, MD
Cardiology · Boynton Beach, FLNPI 1649291113
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,850 of the $5,468 with a category attached, or 88.7%. It is spread thinly across 24 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations.
Across 228 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$799
- Medtronic$695
- Boehringer Ingelheim$612
- Bayer$431
- Amgen$400
- Johnson & Johnson$353
- plus $2K from 18 others
Across 30 payments — averaging $6655.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$173K
- Bayer$26K
What the payments were for
- Travel & lodging$59911%
- Food & beverage$4,85089%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 47 | $799 |
| Medtronic(2 entities) | 7 | $695 |
| Boehringer Ingelheim | 26 | $612 |
| Bayer | 21 | $431 |
| Amgen | 19 | $400 |
| Johnson & Johnson | 17 | $353 |
| Merck | 11 | $326 |
| Pfizer | 15 | $298 |
| Boston Scientific | 13 | $292 |
| AstraZeneca | 15 | $290 |
| E.r. Squibb & Sons, L.L.C. | 10 | $194 |
| Abbott | 5 | $186 |
| Artivion, Inc. | 2 | $103 |
| Cvrx, Inc. | 5 | $100 |
| Atricure, Inc. | 3 | $85 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $74 |
| Edwards Lifesciences | 1 | $58 |
| Novo Nordisk | 1 | $32 |
| Cashflow Solutions, LLC | 2 | $32 |
| Philips North America LLC | 1 | $27 |
| Lilly USA, LLC | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Preventice Services, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$599
- VERQUVO$222
How this compares
$5,468 in reported general payments places this provider in the 85th percentile of 45 cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $197,602 |
| XareltoRivaroxaban | 171 | $183,144 |
| EntrestoSacubitril/Valsartan | 121 | $123,411 |
| Repatha SureclickEvolocumab | 52 | $54,210 |
| JardianceEmpagliflozin | 39 | $50,323 |
| Repatha PushtronexEvolocumab | 29 | $23,719 |
| BrilintaTicagrelor | 15 | $15,883 |
| FarxigaDapagliflozin Propanediol | 11 | $11,160 |
| Valsartan | 417 | $8,892 |
| Nebivolol Hcl | 214 | $8,552 |
| Ranolazine ErRanolazine | 93 | $7,052 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 154 | $5,166 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 183 | $4,738 |
| Rosuvastatin Calcium | 375 | $3,494 |
| Metoprolol Succinate | 245 | $3,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $298 | $197,602184 claims |
| Johnson & JohnsonXarelto | $353 | $183,144171 claims |
| NovartisEntresto | $799 | $123,411121 claims |
| Boehringer IngelheimJardiance | $612 | $50,32339 claims |
| AstraZenecaBrilinta, Farxiga | $290 | $27,04326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 cardiology providers in Florida.
Other cardiology in Boynton Beach
- Shakoor ArainOkeechobee$13K
- Erick CalderonLakewood Ranch$10K
- Melchor GonzalezPalm Coast$8K
- Andres PalomoMiami$7K
- Ariel de la RosaHialeah$7K
- Mayank YadavOrange City$7K
- Mohsen RashdanBoca Raton$5K
- Ramanath RaoZephyrhills$5K
- Akram ElgendyGainesville$5K
- Thomas MathewsBrooksville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.